4-(N,N-二甲基磺酰基)-2-甲基苯硼酸 | 957034-82-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(N,N-二甲基磺酰基)-2-甲基苯硼酸
• 英文名称: 4-(N,N-dimethylsulfamoyl)-2-methylphenylboronic acid
• 英文别名: [4-(dimethylsulphamoyl)-2-methylphenyl]boronic acid；[4-(dimethylsulfamoyl)-2-methylphenyl]boronic acid
• CAS: 957034-82-1
• 化学式: C₉H₁₄BNO₄S
• mdl: MFCD09475839
• 分子量: 243.091
• InChiKey: KNKDICZGYPFTBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.23
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P210,P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P370+P378,P403+P233,P403+P235,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(N,N-Dimethylsulfamoyl)-2-methylphenylboronic acid
Synonyms: N,N-Dimethyl 4-borono-3-methylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(N,N-Dimethylsulfamoyl)-2-methylphenylboronic acid
CAS number: 957034-82-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14BNO4S
Molecular weight: 243.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(N,N-二甲基磺酰基)-2-甲基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium dihydrogenphosphate 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 21.67h， 生成 4-[8-ethyl-2-[2-(1-methyl-4-piperidyl)ethylamino]-7-oxo-pyrido[2,3-d]pyrimidin-6-yl]-N,N,3-trimethyl-benzenesulfonamide
  参考文献：
  名称：

  SERINE/THREONINE KINASE INHIBITORS

  摘要：

  具有公式I或其药用可接受的盐的化合物，其中R1、R2、X1、X2和Ar如本文所定义，是PAK1的抑制剂。还公开了使用这些化合物治疗癌症和增生性疾病的组合物和方法。

  公开号：

  US20140323477A1

文献信息

• New bicyclic compounds as crac channel modulators
  申请人：Almirall, S.A.

  公开号：EP2738172A1

  公开（公告）日：2014-06-04

  The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

  这项发明涉及一种新型化合物，它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物，它们的制备方法以及它们在治疗中的应用。
• DIAZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158040A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• 4-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158066A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• Preparation of highly functionalized 1,5-disubstituted tetrazoles via palladium-catalyzed Suzuki coupling
  作者：Edward J. Hennessy、Mark Cornebise、Lakshmaiah Gingipalli、Tyler Grebe、Sudhir Hande、Valerie Hoesch、Hoan Huynh、Scott Throner、Jeffrey Varnes、Ye Wu

  DOI：10.1016/j.tetlet.2017.03.056

  日期：2017.4

  been achieved through palladium-catalyzed Suzuki coupling. Using appropriately substituted 5-p-toluenesulfonyltetrazoles as substrates (obtained by cycloaddition of a substituted azide with p-toluenesulfonyl cyanide), this methodology provides access to a variety of highly substituted tetrazoles that would be difficult to access otherwise. The procedure is compatible with functional groups commonly found

  通过钯催化的Suzuki偶联已经实现了一系列1，5-二取代的四唑的制备。使用适当取代的5-对甲苯磺酰基四唑作为底物（通过将取代的叠氮化物与对甲苯磺酰基氰基环加成而获得），该方法提供了多种否则难以获得的高度取代的四唑的访问。该程序与药物样分子中常见的官能团兼容，并已用于产生许多具有潜在生物学意义的化合物。
• SUBSTITUTED PHENYLALANINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160244437A1

  公开（公告）日：2016-08-25

  The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.

  本发明涉及取代苯丙氨酸衍生物及其制备方法，以及将其用于生产用于治疗和/或预防疾病的药物，特别是心血管疾病和/或严重围手术期失血的药物。